John M. Zajecka, M.D.

Original Research

Long-Term Efficacy, Safety, and Tolerability of l-Methylfolate Calcium 15 mg as Adjunctive Therapy With Selective Serotonin Reuptake Inhibitors: A 12-Month, Open-Label Study Following a Placebo-Controlled #05#

May 25, 2016

John M. Zajecka, Maurizio Fava, Richard C. Shelton, et al

Original Research

Association of Obesity and Inflammatory Marker Levels on Treatment Outcome: Results From a Double-Blind, Randomized Study of Adjuncve L-Methylfolate Calciumin Paents With MDD Who Are Inadequate Responders to SSRIs

December 23, 2015

Richard C. Shelton, Michael J. Pencina, Lori W. Barrentine, et al

Original Research

Effect of Adjunctive l-Methylfolate 15 mg Among Inadequate Responders to SSRIs in Depressed Patients Who Were Stratified by Biomarker Levels and Genotype: Results From a Randomized Clinical Trial

April 15, 2014

George I. Papakostas, Richard C. Shelton, John M. Zajecka, et al

DELETE Managing the Full Range of Symptoms to Achieve Lasting Remission

Residual Symptoms and Relapse: Mood, Cognitive Symptoms, and Sleep Disturbances

October 29, 2013

John M. Zajecka

Article

Residual Symptoms and Relapse: Mood, Cognitive Symptoms, and Sleep Disturbances

October 15, 2013

John M. Zajecka

Original Research

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Trial of Ziprasidone as Monotherapy for Major Depressive Disorder

December 15, 2012

George I. Papakostas, Ottavio V. Vitolo, Waguih W. IsHak, et al

Educational Activity

Evidence for the Use of <span style="font-variant:small-caps;">l</span>-Methylfolate Combined With Antidepressants in MDD

August 15, 2011

Maurizio Fava, Richard C. Shelton, John M. Zajecka

Letter to the Editor

Oral Divalproex Sodium Loading for Adolescent Outpatients With Acute Mania/Hypomania: A Report of 2 Cases

June 30, 2008

John M. Zajecka, Selika N. Gutierrez

Article

Augmentation Strategies to Increase Antidepressant Tolerability

August 15, 2007

John M. Zajecka

Original Research

The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study: Outcomes From the 2-Year and Combined Maintenance Phases

August 15, 2007

Martin B. Keller, Madhukar H. Trivedi, Michael E. Thase, et al

Original Research

Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study

July 16, 2007

James H. Kocsis, Michael E. Thase, Madhukar H. Trivedi, et al

Educational Activity

Preventing Recurrent Depression: Long-Term Treatment for Major Depressive Disorder

March 15, 2007

Pierre Blier, Martin B. Keller, Mark H. Pollack, et al

Long-Term Efficacy, Safety, and Tolerability of l-Methylfolate Calcium 15 mg as Adjunctive Therapy With Selective Serotonin Reuptake Inhibitors: A 12-Month, Open-Label Study Following a Placebo-Controlled #05#

Association of Obesity and Inflammatory Marker Levels on Treatment Outcome: Results From a Double-Blind, Randomized Study of Adjuncve L-Methylfolate Calciumin Paents With MDD Who Are Inadequate Responders to SSRIs

Effect of Adjunctive l-Methylfolate 15 mg Among Inadequate Responders to SSRIs in Depressed Patients Who Were Stratified by Biomarker Levels and Genotype: Results From a Randomized Clinical Trial

Residual Symptoms and Relapse: Mood, Cognitive Symptoms, and Sleep Disturbances

Residual Symptoms and Relapse: Mood, Cognitive Symptoms, and Sleep Disturbances

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Trial of Ziprasidone as Monotherapy for Major Depressive Disorder

Evidence for the Use of <span style="font-variant:small-caps;">l</span>-Methylfolate Combined With Antidepressants in MDD

Oral Divalproex Sodium Loading for Adolescent Outpatients With Acute Mania/Hypomania: A Report of 2 Cases

Augmentation Strategies to Increase Antidepressant Tolerability

The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study: Outcomes From the 2-Year and Combined Maintenance Phases

Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study

Preventing Recurrent Depression: Long-Term Treatment for Major Depressive Disorder

ELSEWHERE:

FOLLOW US:

John M. Zajecka, M.D.

Long-Term Efficacy, Safety, and Tolerability of l-Methylfolate Calcium 15 mg as Adjunctive Therapy With Selective Serotonin Reuptake Inhibitors: A 12-Month, Open-Label Study Following a Placebo-Controlled #05#

Association of Obesity and Inflammatory Marker Levels on Treatment Outcome: Results From a Double-Blind, Randomized Study of Adjuncve L-Methylfolate Calciumin Paents With MDD Who Are Inadequate Responders to SSRIs

Effect of Adjunctive l-Methylfolate 15 mg Among Inadequate Responders to SSRIs in Depressed Patients Who Were Stratified by Biomarker Levels and Genotype: Results From a Randomized Clinical Trial

Residual Symptoms and Relapse: Mood, Cognitive Symptoms, and Sleep Disturbances

Residual Symptoms and Relapse: Mood, Cognitive Symptoms, and Sleep Disturbances

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Trial of Ziprasidone as Monotherapy for Major Depressive Disorder

Evidence for the Use of <span style="font-variant:small-caps;">l</span>-Methylfolate Combined With Antidepressants in MDD

Oral Divalproex Sodium Loading for Adolescent Outpatients With Acute Mania/Hypomania: A Report of 2 Cases

Augmentation Strategies to Increase Antidepressant Tolerability

The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study: Outcomes From the 2-Year and Combined Maintenance Phases

Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study

Preventing Recurrent Depression: Long-Term Treatment for Major Depressive Disorder

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles